Uh Oh...

[Anonymous]

Savient Reports Batch Failures With New U.S. Gout Medication Krystexxa
By Catherine Larkin - Jan 7, 2011 9:15 AM ET
inShare.0More
Business ExchangeBuzz up!DiggPrint Email .Savient Pharmaceuticals Inc., the drug developer that failed to find a buyer last year, said the manufacturers hired to produce its gout medicine Krystexxa made some batches that failed.

Savient said in a statement today it expects to pay $9 million to $10 million in the next two years to repeat efforts to validate manufacturing at Merck Biomanufacturing Network, a unit of Merck & Co. based in Billingham, U.K. Another contract manufacturer in Israel also reported failures, and remediation is under way, the statement said. The latest two batches there have met specifications, according to Savient.

Krystexxa became available in December to U.S. patients with gout, a type of arthritis in which deposits of uric acid build up around joints, causing pain, swelling and stiffness.

Savient, of East Brunswick, New Jersey, fell 35 cents, or 2.9 percent, to $10.59 at 8:57 a.m. in early trading before the Nasdaq Stock Market opened. The shares fell the most in two years Oct. 25 after the company said it failed to find a buyer.

To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net.

 

[Anonymous]

Savient Reports Batch Failures With New U.S. Gout Medication Krystexxa
By Catherine Larkin - Jan 7, 2011 9:15 AM ET
inShare.0More
Business ExchangeBuzz up!DiggPrint Email .Savient Pharmaceuticals Inc., the drug developer that failed to find a buyer last year, said the manufacturers hired to produce its gout medicine Krystexxa made some batches that failed.

Savient said in a statement today it expects to pay $9 million to $10 million in the next two years to repeat efforts to validate manufacturing at Merck Biomanufacturing Network, a unit of Merck & Co. based in Billingham, U.K. Another contract manufacturer in Israel also reported failures, and remediation is under way, the statement said. The latest two batches there have met specifications, according to Savient.

Krystexxa became available in December to U.S. patients with gout, a type of arthritis in which deposits of uric acid build up around joints, causing pain, swelling and stiffness.

Savient, of East Brunswick, New Jersey, fell 35 cents, or 2.9 percent, to $10.59 at 8:57 a.m. in early trading before the Nasdaq Stock Market opened. The shares fell the most in two years Oct. 25 after the company said it failed to find a buyer.

To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net.

This is par for the course, ineptness to the core. This is why so many questioned this company, opportunity, and all the non sense about interviews and stability of the position. Hacks. This is what happens when every real bio tech shuts the door on your leadership and call your bluff on a product that is irrelevant, over priced, and has no chance. Big pharma laughed out the idea of a partnership and Savient is now scrambling to put the fingers in the dam.... would you want to work for an outfit like this??? Didn't think so. Who is the idiot now, asshole RBD. This company was a joke before the problems leaked, now it is just a good laugh.

 

[Anonymous]

Savient Reports Batch Failures With New U.S. Gout Medication Krystexxa
By Catherine Larkin - Jan 7, 2011 9:15 AM ET
inShare.0More
Business ExchangeBuzz up!DiggPrint Email .Savient Pharmaceuticals Inc., the drug developer that failed to find a buyer last year, said the manufacturers hired to produce its gout medicine Krystexxa made some batches that failed.

Savient said in a statement today it expects to pay $9 million to $10 million in the next two years to repeat efforts to validate manufacturing at Merck Biomanufacturing Network, a unit of Merck & Co. based in Billingham, U.K. Another contract manufacturer in Israel also reported failures, and remediation is under way, the statement said. The latest two batches there have met specifications, according to Savient.

Krystexxa became available in December to U.S. patients with gout, a type of arthritis in which deposits of uric acid build up around joints, causing pain, swelling and stiffness.

Savient, of East Brunswick, New Jersey, fell 35 cents, or 2.9 percent, to $10.59 at 8:57 a.m. in early trading before the Nasdaq Stock Market opened. The shares fell the most in two years Oct. 25 after the company said it failed to find a buyer.

To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net.

Not surprising...... sign me up! What a joke. Amateurs.

 

[Anonymous]

Why do you care so much? Quit posting on this site! You sound like someone who was rejected and is just plain sour about it. You surely are not doing it to save the people who are thinking about working at Savient. Get off of this thread and find something productive to do, you Idiot. We don't care what you have to say.

 

[Anonymous]

Not surprising...... sign me up! What a joke. Amateurs.

Amateurs is correct! Good thing I did not take the bait on this offer, I was about to commit to an interview, things are not great at my current company, but this would be walking into a bee hive of incompetence.

I thought something was "off" during my conversations with leaders, especially the head guy TQ and then the RBD was extremely unprofessional but I thought I was going to need a job, quickly. I of course knew it would have been a temporary stop but this is the confirmation I needed to see what I suspected. They are in over their head and the three blind mice are leading this into the ground. Now I fully get why they so desperately tried to sell off the product and have to avoid the pitfalls of trying their hand at manufacturing and supply and creating demand for such a shaky product.

This was the big knock by the investors, Savient had to find a partner to do the big boys and correct actions. I believe that this hiccups and blunders are indicative of how it would be to work here. Simply just my opinion, but one that many interviewees are feeling. So save your fowl pumping of this being something that it is not for a rainy day!! Facts speak.

 

[Anonymous]

Why do you care so much? Quit posting on this site! You sound like someone who was rejected and is just plain sour about it. You surely are not doing it to save the people who are thinking about working at Savient. Get off of this thread and find something productive to do, you Idiot. We don't care what you have to say.

Pipe down hillbilly. Most disagree with you and your opinion means nothing. I am smarter from reading these posts that shed light into what the recruiters and managers are tying to side step and ignore. Nothing wrong with intelligent intellectual posts from these folks who share on this board. Beat it!

 

[Anonymous]

Amateurs is correct! Good thing I did not take the bait on this offer, I was about to commit to an interview, things are not great at my current company, but this would be walking into a bee hive of incompetence.

I thought something was "off" during my conversations with leaders, especially the head guy TQ and then the RBD was extremely unprofessional but I thought I was going to need a job, quickly. I of course knew it would have been a temporary stop but this is the confirmation I needed to see what I suspected. They are in over their head and the three blind mice are leading this into the ground. Now I fully get why they so desperately tried to sell off the product and have to avoid the pitfalls of trying their hand at manufacturing and supply and creating demand for such a shaky product.

This was the big knock by the investors, Savient had to find a partner to do the big boys and correct actions. I believe that this hiccups and blunders are indicative of how it would be to work here. Simply just my opinion, but one that many interviewees are feeling. So save your fowl pumping of this being something that it is not for a rainy day!! Facts speak.

We DONT CARE what you think you idiot. Get off of our board. Stop talking shit about the position and company. Great, so you passed on it, or maybe were passed on, either way, WE DONT CARE what you have to say. STOP posting on here.

 

[Anonymous]

This is par for the course, ineptness to the core. This is why so many questioned this company, opportunity, and all the non sense about interviews and stability of the position. Hacks. This is what happens when every real bio tech shuts the door on your leadership and call your bluff on a product that is irrelevant, over priced, and has no chance. Big pharma laughed out the idea of a partnership and Savient is now scrambling to put the fingers in the dam.... would you want to work for an outfit like this??? Didn't think so. Who is the idiot now, asshole RBD. This company was a joke before the problems leaked, now it is just a good laugh.

Hysterical. Could not agree more. Some little pussy is getting his feelings hurt by the truth. Crap, how are you all going to handle the real job if it even gets off the ground if you cannot handle the risks and truth on cafe pharma about this position? You will be in tears when every single RHE laughs you out of their office come launch time, if that ever pans out.